Author

Leonhard Muellauer

Observed names: L. Muellauer, Muellauer Leonhard, Muellauer, Leonhard

Institution: Medical University of Vienna

Observed institutions: Comprehensive Cancer Center Vienna, Medical University of Vienna

OpenAlex ID: A5112413856

Lymphocyte-activation gene 3 (LAG-3) expression in the inflammatory microenvironment of glioma.

2020 · Maximilian Mair, Barbara Kiesel, et al. · Journal of Clinical Oncology · 6

Masked Polycythemia Vera (mPV): Results Of An International Study

2013 · Tiziano Barbui, Jürgen Thiele, et al. · Blood · 5

Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial

2020 · Christoph Kornauth, Tea Pemovska, et al. · Blood · 2

Prefibrotic Primary Myelofibrosis As an Entity Distinct from Other Philadelphia-Chromosome Negative Myeloproliferative Neoplasms - Data from the Austrian Reclassification Project

2016 · Georg Jeryczynski, Bettina Gisslinger, et al. · Blood · 2

Comparative Analysis of Japanese and European Typical CLL Patients

2016 · Jun Takizawa, Michaela Gruber, et al. · Blood · 2

Neoadjuvant chemoradiotherapy with ipilimumab and nivolumab in rectal cancer (CHINOREC): A prospective randomized, open-label, multicenter, phase II clinical trial.

2025 · Johannes Laengle, Irene Kuehrer, et al. · Journal of Clinical Oncology · 1

PDF

Tumor-informed ctDNA as an objective marker for postoperative residual disease in epithelial ovarian cancer.

2024 · Valentina Paspalj, Christoph Grimm, et al. · Journal of Clinical Oncology · 1

DNA methylation profiling in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors.

2020 · Angelika Martina Starzer, Gerwin Heller, et al. · Journal of Clinical Oncology · 1

Digital Droplet PCR: Next Generation KIT D816V Testing As Advanced Tool for Diagnosis and Prognostication in Mastocytosis

2017 · Georg Greiner, Michael Gurbisz, et al. · Blood · 1

Calreticulin Mutation Status Predicts Improved Disease Outcome in Prefibrotic Primary Myelofibrosis but Not in WHO-Defined Essential Thrombocythemia

2014 · Heinz Gisslinger, Juergen Thiele, et al. · Blood · 1

Correlation Of Longitudinal Blood Counts With Thromboembolic Complications In WHO 2008 Defined Prefibrotic Primary Myelofibrosis

2013 · Veronika Buxhofer-Ausch, Martin Schalling, et al. · Blood · 1

Histidine Decarboxylase (HDC) as Novel Marker of Immature Neoplastic Mast Cells in Systemic Mastocytosis.

2004 · Maria T. Krauth, Hermine Agis, et al. · Blood · 1

Retrospective analysis of real-world elacestrant use in two large Austrian cancer centers

2026 · Lisa Vesenmayer, Simon Udovica, et al. · Breast Care

PDF

First-Line ALK-Directed Therapy in Metastatic Renal Cell Carcinoma

2026 · Taedcke Roman, Mayr Michael, et al. · Annals of Case Reports

PDF

CD31により評価された微小血管密度は転移性結腸直腸癌におけるベバシズマブ治療に対する臨床的利点を予測する:カペシタビンとイリノテカン+ベバシズマブ併用後のカペシタビンとイリノテカン+ベバシズマブの翻訳前向き第II相試験,およびmCRCの患者における逆シーケンスのトランスレーショナル前向き第II相研究の結果,カペシタビンとイリノテカン+ベバシズマブのトランスレーショナル前向き第II相試験の結果【JST・京大機械翻訳】

2020 · Bianconi Daniela, Herac Merima, et al. · Therapeutic Advances in Medical Oncology

Molecular Quantification of Tissue Mast Cell Burden in Systemic Mastocytosis: A New Approach for Diagnostics and Prognostication

2018 · Greiner Georg, Michael Gurbisz, et al. · Blood

Next-Generation Functional Drug Screening for Patients with Aggressive Hematologic Malignancies

2017 · Philipp Bernhard Staber, Berend Snijder, et al. · Blood

Impact of High Molecular Risk Mutations on Overall Survival in WHO-Defined Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis

2016 · Heinz Gisslinger, Martin Schalling, et al. · Blood

Survival in Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis - Correlation of Clinical Phenotype with Histomorphological Diagnosis

2016 · Georg Jeryczynski, Albert Woelfler, et al. · Blood

Clinical Impact of Bone Marrow Morphology for the Diagnosis of Essential Thrombocythemia: Comparison Between the British Standards (BCSH) and the WHO Criteria

2015 · Georg Jeryczynski, Juergen Thiele, et al. · Blood

447 Extended Analysis for Cancer Treatment (EXACT): Interim analysis of a prospective precision medicine trial

2015 · G. Prager, M. Unseld, et al. · European Journal of Cancer

The epigenetic reader brd4 serves as a novel marker and target in aggressive systemic mastocytosis and mast cell leukemia

2014 · Ghaith Wedeh, Sabine Cerny‐Reiterer, et al. · Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory)

Imatinib Inhibits SCF-Induced Development Of Human Mast Cells In Vitro and Induces Profound and Selective Mast Cell Deficiency In Patients With Ph+ CML

2013 · Sabine Cerny-Reiterer, Anja Rabenhorst, et al. · Blood

Sa1593 A Pilot Study of Confocal LASER Endomicrosopy for Staging and Follow-up of Gastrointestinal MALT-Lymphoma: Interim Analysis of 15 Consecutive Cases

2013 · Werner Dolak, Barbara Kiesewetter, et al. · Gastrointestinal Endoscopy

Abstract 4257: Genome-wide CpG island methylation analysis identifies tumor specifically methylated genes in non-small cell lung cancer patients.

2013 · Gerwin Heller, Valerie Babinsky, et al. · Cancer Research

Works count: 32

Citation count: 24

H-index: 2

I10-index: